Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
Date:4/30/2008

SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results and highlights for the first quarter ended March 31, 2008.

"We made significant progress in both of our development programs during the first quarter," said Steve Worland, Ph.D., President and CEO of Anadys. "We successfully completed preclinical evaluation of ANA598, our non-nucleoside polymerase inhibitor for the treatment of hepatitis C, and have subsequently filed an IND for this product candidate. We also commenced dosing with ANA773, our oral TLR7 agonist prodrug, in patients with advanced cancer." Providing an updated cash outlook for 2008, Dr. Worland added, "Based on promising results from the preclinical evaluation of ANA598, we have made the strategic decision to accelerate certain non-clinical development activities for ANA598 into 2008 and now expect our cash utilization this year to be in the range of $29 million to $31 million."

Financial Results

As of March 31, 2008, the Company's cash, cash equivalents and securities available-for-sale totaled $48.8 million compared to $56.5 million as of December 31, 2007.

During the first quarter of 2008 the Company had no revenue, compared to $1.1 million in revenue for the same quarter of 2007. The revenue in the first quarter of 2007 was primarily derived from the amortization of an upfront payment and milestone payment under a prior collaboration.

Research and development expenses were $6.0 million for the first quarter of 2008 compared to $6.7 million for the first quarter of 2007. The $0
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
3. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
4. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
5. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
6. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
9. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
11. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:ROBODOC(R) Emerges as a Curexo Technology Company at Upcoming Orthopaedic Surgeons Conference in San Francisco 2MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference 2MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference 3US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 2US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 4US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 5US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 6US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 7US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 8US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 9US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 10US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 11US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 12US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 13US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 14US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 15US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 16US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 17US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 18US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 19US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 20US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 21US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 22US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 23US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 24US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 25US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 26